Loading…
Loading…
CHNXF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CHNXF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CHNXF and 80,000+ other tickers.
See exactly how CHNXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CHNXF and 80,000+ other tickers.
ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development. Its developmental pipeline includes a range of specialized products: Ortho-R, a specific formulation designed for rotator cuff injuries; Ortho-M, a biopolymer addressing meniscus repair; Ortho-C, another biopolymer for the regeneration of articular cartilage; and Ortho-V, a biopolymer developed to facilitate…
ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) provided highlights for its third quarter of fiscal year 2024, which included the reduction of operating losses by 73% fiscal year to date compared with the previous year. The clinical-stage regenerative medicine company also said it improved its working capital by $3.6 million since fiscal 2023 year end.
ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that its proprietary chitosan/platelet-rich plasma (PRP)-based biopolymer matrix, ORTHO-R, has successfully demonstrated protection from joint degeneration post-meniscal repair surgery in a large animal study. The clinical-stage regenerative medicine company said a study of 22 mature sheep provided the first evidence that treatment including its chitosan-based biopolymer and PRP prevents structural changes to radially incised and sutured menisci in a large animal model.
ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors it has launched a new development program targeting significant unmet medical needs in the multi-billion dollar burn and skin repair market. Proof of concept studies have already been completed and results will be announced in the coming weeks, the company said.
Significant unmet medical needs in US $19B burn and skin defects market New patent in US and Canada supports ChitogenX' proprietary chitosan-based biopolymer as ideal combination with cellular regeneration technologies Potential for streamlined regulatory process, and faster path to commercialization Both burn and skin repair program to be primarily funded by recently awarded $3.4 M grant MONTREAL , Nov. 7, 2023 /PRNewswire/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that it has launched a new development program targeting significant unmet medical needs in the burn and skin repair market, currently valued at US $19B and growing at 5% + CAGR through 2032. Proof of concept studies have already been successfully completed and results will be the subject of news releases in the coming weeks.
ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that it made significant progress in deleveraging its balance sheet and improving its working capital as it continued to advance its ORTHO-R technology platform during the second quarter of its 2024 financial year. Among the corporate highlights for the quarter ended July 31, 2023, the company noted an agreement with Bruder Consulting & Venture Group to serve as its exclusive advisory firm for the pursuit of new strategic development partnerships.